tetano
Editor, Senior Moderator
Ann Palliat Med
. 2020 Jul 20;apm-20-1273.
doi: 10.21037/apm-20-1273. Online ahead of print.
Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Yuhong Chen[SUP] 1 [/SUP], Kun Zhang[SUP] 2 [/SUP], Guijun Zhu[SUP] 2 [/SUP], Lixia Liu[SUP] 2 [/SUP], Xixin Yan[SUP] 3 [/SUP], Zhigang Cai[SUP] 3 [/SUP], Zhongheng Zhang[SUP] 4 [/SUP], Haijun Zhi[SUP] 5 [/SUP], Zhenjie Hu[SUP] 6 [/SUP]
Affiliations
Abstract
Background: In December, 2019, a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. We aimed to clarify the epidemiology, laboratory examinations, imaging findings, and treatment of critically ill patients with COVID-19 in Hebei province, China.
Methods: In this retrospective study, the demographic, laboratory and imaging, and treatment data of patients with severe COVID-19 treated in 13 designated hospitals in Hebei were collected and analyzed.
Results: A total of 319 severe COVID-19 patients were treated at the 13 designated hospitals between 22 January, 2020 and 25 March, 2020. Eventually, 51 critically ill (31 severe cases and 20 critically severe cases) patients were included in the analysis. The patients had an average age of 58.9?13.7 years, and 27 (52.9%) were men. Twenty-one (41.2%) were familial cluster, and 33 (64.7%) had chronic illnesses. The patients in critically severe group had longer duration from symptom to confirmation, more severe infections, more severe lung injury, and a lower percentage of lymphocytes. All 51 patients received antiviral drugs, 47 (92.2%) received antibacterial agents, 49 (96.1%) received traditional Chinese drugs, and 46 (90.2%) received methylprednisolone. The critically severe patients received more fluid and more diuretic treatment; 14 (70.0%) required invasive mechanical ventilation, and 13 (65.0%) developed extrapulmonary complications.
Conclusions: COVID-19 patients who had underlying diseases and longer confirmation times were more likely to progress to critically severe COVID-19. These patients also presented with a higher risk of respiratory depression, circulatory collapse, extrapulmonary complications, and infection.
Keywords: 2019 novel coronavirus; 2019-nCoV; SARS-CoV-2; critically ill; novel coronavirus disease 2019 (COVID-19).
. 2020 Jul 20;apm-20-1273.
doi: 10.21037/apm-20-1273. Online ahead of print.
Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Yuhong Chen[SUP] 1 [/SUP], Kun Zhang[SUP] 2 [/SUP], Guijun Zhu[SUP] 2 [/SUP], Lixia Liu[SUP] 2 [/SUP], Xixin Yan[SUP] 3 [/SUP], Zhigang Cai[SUP] 3 [/SUP], Zhongheng Zhang[SUP] 4 [/SUP], Haijun Zhi[SUP] 5 [/SUP], Zhenjie Hu[SUP] 6 [/SUP]
Affiliations
- PMID: 32692230
- DOI: 10.21037/apm-20-1273
Abstract
Background: In December, 2019, a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. We aimed to clarify the epidemiology, laboratory examinations, imaging findings, and treatment of critically ill patients with COVID-19 in Hebei province, China.
Methods: In this retrospective study, the demographic, laboratory and imaging, and treatment data of patients with severe COVID-19 treated in 13 designated hospitals in Hebei were collected and analyzed.
Results: A total of 319 severe COVID-19 patients were treated at the 13 designated hospitals between 22 January, 2020 and 25 March, 2020. Eventually, 51 critically ill (31 severe cases and 20 critically severe cases) patients were included in the analysis. The patients had an average age of 58.9?13.7 years, and 27 (52.9%) were men. Twenty-one (41.2%) were familial cluster, and 33 (64.7%) had chronic illnesses. The patients in critically severe group had longer duration from symptom to confirmation, more severe infections, more severe lung injury, and a lower percentage of lymphocytes. All 51 patients received antiviral drugs, 47 (92.2%) received antibacterial agents, 49 (96.1%) received traditional Chinese drugs, and 46 (90.2%) received methylprednisolone. The critically severe patients received more fluid and more diuretic treatment; 14 (70.0%) required invasive mechanical ventilation, and 13 (65.0%) developed extrapulmonary complications.
Conclusions: COVID-19 patients who had underlying diseases and longer confirmation times were more likely to progress to critically severe COVID-19. These patients also presented with a higher risk of respiratory depression, circulatory collapse, extrapulmonary complications, and infection.
Keywords: 2019 novel coronavirus; 2019-nCoV; SARS-CoV-2; critically ill; novel coronavirus disease 2019 (COVID-19).